829 related articles for article (PubMed ID: 17113714)
21. Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences.
Rodrigues AD; Rushmore TH
Curr Drug Metab; 2002 Jun; 3(3):289-309. PubMed ID: 12083322
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency.
Linder MW; Prough RA; Valdes R
Clin Chem; 1997 Feb; 43(2):254-66. PubMed ID: 9023127
[TBL] [Abstract][Full Text] [Related]
23. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.
Thuerauf N; Lunkenheimer J
Eur Arch Psychiatry Clin Neurosci; 2006 Aug; 256(5):287-93. PubMed ID: 16783493
[TBL] [Abstract][Full Text] [Related]
24. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance.
Rosemary J; Adithan C
Curr Clin Pharmacol; 2007 Jan; 2(1):93-109. PubMed ID: 18690857
[TBL] [Abstract][Full Text] [Related]
25. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
26. Drug metabolism and variability among patients in drug response.
Wilkinson GR
N Engl J Med; 2005 May; 352(21):2211-21. PubMed ID: 15917386
[No Abstract] [Full Text] [Related]
27. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
Lynch T; Price A
Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
[TBL] [Abstract][Full Text] [Related]
28. Adverse drug reaction monitoring in Jena. Relevance of polymorphic drug metabolizing enzymes for inducing adverse drug reactions.
Hippius M; Buchardt C; Farker K; Kuhn UD; Reimann IR; Hoffmann A
Exp Toxicol Pathol; 2003 Jun; 54(5-6):417-21. PubMed ID: 12877354
[TBL] [Abstract][Full Text] [Related]
29. Cytochrome p450 genotyping by multiplexed real-time dna sequencing with pyrosequencing technology.
Eriksson S; Berg LM; Wadelius M; Alderborn A
Assay Drug Dev Technol; 2002 Nov; 1(1 Pt 1):49-59. PubMed ID: 15090156
[TBL] [Abstract][Full Text] [Related]
30. Clinical consequences of cytochrome P450 2C9 polymorphisms.
Kirchheiner J; Brockmöller J
Clin Pharmacol Ther; 2005 Jan; 77(1):1-16. PubMed ID: 15637526
[TBL] [Abstract][Full Text] [Related]
31. [State of the art of pharmacogenetic diagnostics in drug therapy].
Kirchheiner J; Seeringer A; Brockmöller J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Oct; 49(10):995-1003. PubMed ID: 17013776
[TBL] [Abstract][Full Text] [Related]
32. Polymorphisms of human cytochrome P450 2C9 and the functional relevance.
Zhou SF; Zhou ZW; Huang M
Toxicology; 2010 Dec; 278(2):165-88. PubMed ID: 19715737
[TBL] [Abstract][Full Text] [Related]
33. [Individualization of drug therapy and pharmacogenetics].
Yamamoto I; Azuma J
Nihon Rinsho; 1998 Mar; 56(3):579-83. PubMed ID: 9549339
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.
Ingelman-Sundberg M
Trends Pharmacol Sci; 2004 Apr; 25(4):193-200. PubMed ID: 15063083
[TBL] [Abstract][Full Text] [Related]
35. Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.
Kirchheiner J; Rodriguez-Antona C
CNS Drugs; 2009; 23(3):181-91. PubMed ID: 19320528
[TBL] [Abstract][Full Text] [Related]
36. Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders.
Kirchheiner J; Bertilsson L; Bruus H; Wolff A; Roots I; Bauer M
Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S235-43. PubMed ID: 14677085
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphisms associated with antiepileptic metabolism.
Lopez-Garcia MA; Feria-Romero IA; Fernando-Serrano H; Escalante-Santiago D; Grijalva I; Orozco-Suarez S
Front Biosci (Elite Ed); 2014 Jun; 6(2):377-86. PubMed ID: 24896213
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetics and interactions of antidepressants in the treatment of co-morbid illness.
Mihaljević-Peles A; Sagud M; Bozina N; Zivković M; Jovanović N
Psychiatr Danub; 2009 Sep; 21(3):399-400. PubMed ID: 19794364
[TBL] [Abstract][Full Text] [Related]
39. Obstetric therapeutics-how pharmacogenetics may inform drug therapy for pregnant women in the future.
Haas DM
Obstet Gynecol Surv; 2013 Sep; 68(9):650-4. PubMed ID: 25102121
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenetics and psychopharmacotherapy.
Poolsup N; Li Wan Po A; Knight TL
J Clin Pharm Ther; 2000 Jun; 25(3):197-220. PubMed ID: 10886465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
